Zealand Pharma: Petrelintide emerges as a key project in the obesity market

Zealand Pharma is a Danish biotechnology company focused on the discovery, design, and development of innovative peptide-based drugs, primarily for the treatment of metabolic and gastrointestinal diseases, obesity, diabetes, and rare diseases with unmet medical needs. Founded in 1998 and listed on Nasdaq Copenhagen, the company has an extensive pipeline of drug candidates in various clinical development phases and collaborates closely with major pharmaceutical partners, including Roche and Boehringer Ingelheim, to advance promising therapeutics...